Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
A fetus is the prenatal stage of a viviparous mammal between the embryonic stage and birth; in humans, this begins at the ninth week of gestation. In pharmacology, the fetus is not classified as a molecular target but is considered a highly sensitive patient population and a site for potential drug-induced toxicity or therapeutic intervention. Drugs reaching the fetus must typically cross the placental barrier, where they may interact with fetal-specific isoforms of enzymes or receptors. Understanding the physiological and developmental state of the fetus is essential for evaluating the safety profiles of maternal medications and for the field of fetal therapy, which aims to treat conditions like congenital diaphragmatic hernia or cardiac arrhythmias in utero.
The fetus is a multicellular organism rather than a molecular target. Drugs interact with specific receptors, enzymes, or signaling pathways within fetal tissues or the placenta to exert therapeutic or toxic effects (e.g., corticosteroids inducing surfactant production via glucocorticoid receptors).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fetus.